Enifer has secured a funding of €36M for the construction of its new PEKILO® mycoprotein factory in Finland. With already existing collaborations with the world’s leading food and feed companies, the company states that the factory will convert food industry side streams into Enifer’s sustainable PEKILO® fungi-based protein ingredients.
Finnish mycoprotein company Enifer has announced the completion of a €36M funding package that enables it to start constructing a unique food-grade mycoprotein factory in Kirkkonummi, Finland. The factory, which is set for completion by the end of 2025 and projected to cost €33M, will convert food industry side streams into Enifer’s sustainable PEKILO® fungi-based protein ingredients. The plant will be the world’s first commercial plant to produce such a mycoprotein ingredient from sidestream raw materials.
“At Enifer, we’re extremely excited to announce the kick-off of our first factory investment project. For over half a century, Kantvik has been at the heart of Finnish bioindustries, and I could not think of a better location to bring PEKILO® fermentation back to life. I would like to thank our new investors, in particular Taaleri Bioindustry and the Finnish Climate Fund, for joining us in our mission. Mycoprotein is the missing ingredient for a more sustainable food chain – the facility in Kantvik serves as a key steppingstone on our path to making mycoprotein a cornerstone of protein supply, with several future factories already being planned,” says Simo Ellilä, CEO and co-founder of Enifer.
The new funding package comprises a new €15M Series B equity funding round led by the Finnish private equity fund Taaleri Bioindustry Fund I, with follow-on investments from existing shareholders Nordic Foodtech VC, Voima Ventures, Valio, and Laine Holding. This funding is complemented by the Finnish Climate Fund, which has extended a €7M capital loan to support the project and a €2M Climate and Environmental Loan provided by Finnvera. This funding comes on top of the previously reported €12M recycling and reuse investment grant from Business Finland, making the factory fully funded.
“We are very happy to start cooperation with Enifer. We believe that there is an increased need for alternative proteins as the global population grows. Demand is also supported globally by environmental and ethical considerations. Taaleri Bioindustry Fund I’s investment enables commercial scale production. We are confident in Enifer’s opportunities to expand,” comments Tero Saarno, Managing Director at Taaleri Bioindustry.
The new factory, which will begin ramping up operations in 2026, will produce up to 3,000 tons of PEKILO® a year, which is enough to cover the annual protein needs of approximately 40,000 people.
The company emphasizes that the production of PEKILO® mycoprotein has a low carbon footprint and requires minimal land and water, making it a very sustainable alternative to animal and plant proteins.
PEKILO® mycoprotein is produced by cultivating a specific species of fungus in a fermentation process that is not too distinct from brewing beer or making soy sauce. The produced PEKILO® mycoprotein powder contains a lot of high-quality protein and fiber. It is also neutral in color and taste, making it an excellent source of nutrition in the most diverse food applications. Enifer and its partners have already demonstrated its use across meat and dairy alternatives, baking, pastries and snacks.
At its core, the factory will harbor a full-sized industrial fermenter, standing more than 12 meters tall and measuring more than 4.5 meters in diameter, in which the PEKILO® mycoprotein is grown. The PEKILO® fermentation process was originally developed in Finland in the 1970s and used to upcycle forest industry side streams into feed-grade mycoprotein. Enifer has breathed new life into this unique innovation, adapting it to new raw material streams from food and agricultural industries and developing a food-grade version of the mycoprotein ingredient.
The company will file for Novel Foods approval of the novel ingredient in 2024 and expects to receive approval during 2026.
